Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action Lawsuit Update

• Company: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
• Lead Plaintiff Deadline: September 14, 2026
• Class Period: August 1, 2025 - May 15, 2026
• Stock Drop: April 29, 2026 - REGN fell $45.41 (about 6.2%) to $686.36; May 18, 2026 - REGN fell $68.57 (about 9.8%) to $629.68
• Lawsuit Type: Securities Class Action

Introduction

A securities class action was filed on July 16, 2026, in the United States District Court for the Southern District of New York against Regeneron Pharmaceuticals, Inc., co-founder, President, Chief Executive Officer, and Co-Chairman George D. Yancopoulos, Senior Vice President and Clinical Development Unit Head of Oncology Israel Lowy, and Senior Vice President of Investor Relations and Strategic Analysis Ryan Crowe. The lawsuit covers investors who purchased or otherwise acquired REGN common stock between August 1, 2025 and May 15, 2026, inclusive.

The case turns on a high-stakes melanoma trial. According to the complaint, Regeneron told investors that the Phase III study of fianlimab, its LAG-3 antibody, in combination with Libtayo, its PD-1 inhibitor cemiplimab, was positioned for success as a first-line treatment for metastatic or locally advanced melanoma. The public story was confident: slow event accrual could mean patients were doing well, the study was conservatively powered, and the drug combination might deliver meaningful clinical differentiation.

The alleged hidden reality was darker. Plaintiff claims the slowdown was not simply a sign of durable treatment benefit, but a structural risk to the trial's statistical validity. The complaint alleges that Regeneron's preliminary assumptions were fundamentally flawed, that the active treatment arm was not delivering the differentiated efficacy profile defendants had promoted, and that a late protocol amendment was needed to force a readout.

Then the market got two shocks. First, Regeneron disclosed that the primary analysis would expand to include all enrolled patients with at least six months of follow-up, prompting analysts to question whether the study could show statistical significance. Weeks later, the company announced that the Phase III Fianlimab-Libtayo Study did not reach statistical significance on its primary endpoint. REGN fell sharply after each disclosure, and the Regeneron shareholder lawsuit followed.

Backdrop and Business Context

Regeneron Pharmaceuticals was founded in 1988 by Leonard S. Schleifer, with George D. Yancopoulos joining shortly afterward as the scientific co-founder, in the Tarrytown, New York orbit where the company remains headquartered. The name reflected the original mission of regenerating neurons, but the company's defining strategic thread became broader: platform-driven biology translated into antibody and biologic medicines. Regeneron went public on Nasdaq in April 1991, with sources reporting 4.5 million shares offered at $22 per share and gross proceeds of about $99 million.

Today, Regeneron operates as an integrated biotechnology company that discovers, develops, manufactures, and commercializes prescription medicines for serious diseases. It generates revenue through direct drug sales, collaboration profit-sharing, royalties, licensing, and milestone payments, including major economics tied to products such as EYLEA, Dupixent, and Libtayo. Regeneron reported full-year 2025 revenue of about $14.34 billion and reported 15,410 full-time employees. Regeneron competes in highly competitive biotechnology and pharmaceutical markets, with competitors varying by product and disease area.

The company's model depends on clinical execution. Regeneron's pipeline spans ophthalmology, immunology, oncology, cardiovascular and metabolic disease, rare disease, and other specialty markets. Regeneron’s public filings identify Libtayo as a marketed oncology product, while the complaint focuses on the Phase III fianlimab-Libtayo study in advanced melanoma. That is where the complaint places its focus: according to the complaint, Regeneron's public confidence in the fianlimab-Libtayo melanoma study collided with undisclosed risks created by slow event accrual, altered protocol mechanics, and ultimately a failed primary endpoint.

Promises Made vs. Reality

The alleged misconduct began on August 1, 2025, when Regeneron released second quarter 2025 results and held a shareholder call. Yancopoulos told investors that Libtayo was being tested with fianlimab in a pivotal first-line advanced melanoma trial, a setting where the combination had generated "compelling preliminary efficacy data" when compared cross-trial to PD-1 monotherapy. He acknowledged that enrollment for the progression-free survival cohort had completed in January as expected, but said results were now anticipated in late 2025 or early 2026 because the blinded PFS event rate accrual had slowed.

When pressed by an analyst about the slowing event rate and confidence in the readout, Yancopoulos did not describe the delay as a sign of heightened clinical or statistical danger. Instead, he said investors could speculate about what fewer events meant, while explaining that the study was powered to show at least the effect competitors had shown, with room to show an even better effect. The complaint alleges that this framing omitted the core risk: the slowdown would later require a protocol change and implied increased risk of a negative outcome.

By November 17, 2025, the messaging had grown more expansive. At the 7th Annual Wolfe Research Healthcare Conference, Lowy described Regeneron as now "comfortably viewed as a serious oncology company" and called the LAG-3 PD-1 combination study the "next big thing" for the company. He said prior cohorts had shown a response rate close to 60% and PFS that had "certainly outperformed" available competition. Addressing concerns that the control arm might perform unexpectedly well, Lowy said Regeneron had taken a conservative approach and was powered to win even if pembrolizumab surprised. He added, "We believe that this is because the test arms are performing well," while acknowledging that "we won't know until we know." He closed by saying the company was "cautiously optimistic."

Crowe continued the theme in December. At the Evercore healthcare conference on December 2, 2025, he said the ideal Phase III outcome would replicate the Phase I pooled cohorts, citing a 57% response rate and 24-month pooled median PFS. He described a result that not only beat pembrolizumab, but was competitive across the field. The next day, at Citi's Annual Global Healthcare Conference, Crowe told investors Regeneron had "a lot of hope and confidence" that fianlimab plus Libtayo could generate meaningful differentiation against current standards of care. He pointed again to Phase I/II results and said even approaching those results would represent a meaningful advance for first-line advanced melanoma.

The assurances continued into March 2026. At the TD Cowen 46th Annual Health Care Conference, Crowe said the company was blinded to the data and did not know why events had slowed. But he also presented the favorable theory: Regeneron hoped responses were durable and that patients were not progressing. He stated that the study had been designed with statistical powering that management was "very confident" would demonstrate the result. A week later, at the Leerink Global Healthcare Conference, he framed the slowdown as a choice between two possibilities: on the negative side, pembrolizumab was doing "something miraculous and amazing," or, on the positive side, the active arms were doing well and approaching the activity shown in early human studies. According to the complaint, defendants left out the third scenario that later materialized: the fianlimab-Libtayo combination was simply not as effective as defendants had suggested.

The first crack came on April 29, 2026. Regeneron disclosed that the trial's primary analysis of progression-free survival would consider all patients enrolled in the study with a minimum follow-up of six months. Yancopoulos nevertheless continued to describe fianlimab-Libtayo as among Regeneron's "potential blockbusters" and pointed to the melanoma opportunity as the center of excitement. On May 12, 2026, Crowe told investors the global metastatic melanoma market opportunity was in the range of $2 billion to $3 billion, said Regeneron believed it had a potentially differentiated efficacy profile, and explained that the protocol amendment had been made because of slow event rates. Three days later, Regeneron announced that the Phase III trial did not reach statistical significance for its primary endpoint. As alleged in the complaint, defendants' repeated confidence, favorable interpretations of the event slowdown, and minimization of protocol risk created a misleading picture of the trial's true risk profile and artificially inflated investor expectations.

Timeline of Alleged Misconduct and Disclosures

Class Period: August 1, 2025 -- May 15, 2026, inclusive.

• Mid-2022: Trial development. Regeneron's Phase III Fianlimab-Libtayo Study commenced enrollment.
• January 2025: Trial enrollment milestone. Enrollment for the progression-free survival cohort was completed, according to defendants' later statements.
• August 1, 2025: Class period begins. Regeneron released second quarter 2025 results and held a same-day shareholder call. Yancopoulos disclosed that results had been delayed because blinded PFS event rate accrual had slowed, while emphasizing compelling preliminary efficacy data and the study's powering.
• November 17, 2025: Investor conference statement. Lowy presented at the 7th Annual Wolfe Research Healthcare Conference, describing the fianlimab-Libtayo readout as the company's "next big thing," citing prior response and PFS data, and stating that slow event accrual was believed to reflect test arms performing well.
• November to December 2025: Protocol amendment period. According to Crowe's later May 12, 2026 explanation, Regeneron submitted the protocol amendment to global regulatory authorities in the "November, December time frame."
• December 2, 2025: Investor conference statement. Crowe presented at the Evercore 8th Annual Healthcare Conference, describing the ideal outcome as replication of Phase I pooled cohort data and stating that a low-to-mid-teens median PFS could be practice changing depending on magnitude.
• December 3, 2025: Investor conference statement. Crowe presented at the Citi Annual Global Healthcare Conference, saying Regeneron had "a lot of hope and confidence" in meaningful differentiation and expected data in the first half of 2026.
• March 4, 2026: Investor conference statement. Crowe presented at the TD Cowen 46th Annual Health Care Conference, said Regeneron was blinded to the data, expressed high hopes, and said the study had statistical powering management was "very confident" would demonstrate the result.
• March 11, 2026: Investor conference statement. Crowe presented at the Leerink Global Healthcare Conference, said the trial was still on track for a first-half readout, and framed the slowing event rate as either pembrolizumab doing "something miraculous and amazing" or the active arms doing quite well.
• April 29, 2026: Alleged Partial Corrective Disclosure and Market Reaction. Regeneron issued first quarter 2026 results and held an earnings call. Yancopoulos disclosed that the primary PFS analysis would consider all patients enrolled in the study with at least six months of follow-up. REGN fell from $731.77 on April 28, 2026 to $686.36 on April 29, 2026, a decline of about 6.2%.
• April 29 to May 2026: Analyst reaction. Wells Fargo stated the stock decline was primarily due to the expanded PFS cohort, which raised concerns that the underlying PFS benefit may be insufficient to show statistical significance. Evercore cited a protocol amendment changing the statistical analysis plan and said preliminary assumptions were "way off."
• May 12, 2026: Investor conference statement. Crowe presented at the Bank of America Global Healthcare Conference 2026, described a $2 billion to $3 billion global metastatic melanoma market opportunity, maintained that Regeneron had a potentially differentiated efficacy profile, and explained that the protocol change was made because of slow event rates.
• May 15, 2026: Alleged Corrective Disclosure. Regeneron issued a press release titled "Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor)," announcing that the trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival.
• May 18, 2026: Market reaction. REGN fell from $698.25 on May 15, 2026 to $629.68 on May 18, 2026, a decline of about 9.8%.
• July 16, 2026: Complaint filed. Plaintiff Allen Cheatham filed the Regeneron securities class action in the Southern District of New York.

Investor Harm and Market Reaction

The first alleged corrective event occurred on April 29, 2026, when Regeneron disclosed that the Phase III Fianlimab-Libtayo Study's primary analysis of progression-free survival would be expanded to consider all enrolled patients with a minimum follow-up of six months. REGN fell from $731.77 per share on April 28, 2026 to $686.36 per share on April 29, 2026, a one-day decline of $45.41, or about 6.2%. Analysts immediately focused on the study design implications. Wells Fargo attributed the share decline primarily to Regeneron's decision to expand the PFS cohort to include all enrolled patients, noting that the move raised investor concerns that the underlying PFS benefit may be insufficient to show statistical significance. Evercore wrote that Regeneron needed a protocol amendment changing the statistical analysis plan to essentially ensure timing for the readout and observed that the preliminary assumptions were "way off."

The second and larger blow came after the market closed on May 15, 2026, when Regeneron announced that the Phase III Fianlimab-Libtayo Study did not reach statistical significance for its primary PFS endpoint. REGN fell from $698.25 per share on May 15, 2026 to $629.68 per share on May 18, 2026, a one-day decline of $68.57, or about 9.8%.

The complaint cites analyst reactions tying the miss to the very risks allegedly concealed during the class period. Citi downgraded Regeneron to Neutral and cut its price target by more than 22%, stating that the current dataset did not support regulatory filing or any commercial value in its model. Bernstein highlighted that the problem was underwhelming performance of the investigational arm, not control-arm overperformance, and questioned whether expansion of the primary analysis set diluted the hazard ratio by adding patients not originally part of the PFS cohort.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 against all defendants, and Section 20(a) control-person claims against the individual defendants. Regeneron is alleged to be liable for the statements and conduct of its executives, while Yancopoulos, Lowy, and Crowe are alleged to have controlled or participated in the challenged communications.

Defendants are Regeneron Pharmaceuticals, Inc., George D. Yancopoulos (Co-Founder, President, Chief Executive Officer, and Co-Chairman), Israel Lowy (Senior Vice President and Clinical Development Unit Head of Oncology), and Ryan Crowe (Senior Vice President of Investor Relations and Strategic Analysis).

Scienter allegations center on defendants' alleged knowledge of, access to, or reckless disregard for non-public information, data, and metrics showing that the prolonged event rate slowdown created structural risk to the trial's statistical validity. The complaint emphasizes defendants' public posture as blinded observers while allegedly tracking stagnating event accumulation, submitting a protocol amendment months before disclosure, and continuing to promote confidence in the study. No insider sales are alleged in the complaint, and no confidential witnesses are cited.

Procedurally, the case is at the complaint stage and seeks class treatment for investors who purchased or otherwise acquired Regeneron common stock during the class period and were damaged after the alleged corrective disclosures. The complaint demands a jury trial and seeks damages, interest, attorneys' fees, expert fees, and costs. Lead plaintiff submissions are due September 14, 2026.

How to Check Whether You May Be Eligible for the Regeneron Pharmaceuticals, Inc. (REGN) Class Action

• Confirm you purchased REGN shares during the August 1, 2025 to May 15, 2026 class period
• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding the lead plaintiff deadline, eligibility, and any potential rights in the litigation

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.